title: Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation.
abstract: The infused stem cell autograft in autologous stem cell transplantation (ASCT) has been viewed mainly as hematologic rescue from the myelosuppressive side effect of conditioning regimens. However, recent reports have shown that the immune effector cells collected at the same time as the stem cells can produce an autologous graft-versus-tumor effect, similar to the graft-versus-tumor effect seen in allogeneic stem cell transplantation without the detrimental effects of graft-versus-host disease. In this article, we review the different immune effector cells collected and infused from the stem cell autograft and their association with clinical outcome post-ASCT, suggesting that ASCT can be viewed not only as a therapeutic maneuver to recover bone marrow function after deliver high-dose chemotherapy, but also as an adoptive immunotherapeutic intervention capable of eradicating residual tumor cells in patients with cancer.
authors: Luis F Porrata, Svetomir N Markovic, Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, United States.
authors: Luis F
authors: LF
authors: Porrata
authors: Svetomir N
authors: SN
authors: Markovic
references: Biol Blood Marrow Transplant. 2008 Jan;14(1):116-24
references: 18158968
references: Leukemia. 2004 Jun;18(6):1085-92
references: 15042106
references: Nat Rev Immunol. 2002 Dec;2(12):957-64
references: 12461568
references: Nature. 2001 May 17;411(6835):385-9
references: 11357147
references: Leukemia. 2002 Jul;16(7):1311-8
references: 12094255
references: Clin Cancer Res. 2004 Aug 1;10(15):5076-86
references: 15297410
references: Blood. 1991 Sep 1;78(5):1212-5
references: 1878588
references: Exp Oncol. 2008 Sep;30(3):240-3
references: 18806749
references: Clin Cancer Res. 2003 Jan;9(1):195-200
references: 12538469
references: Bone Marrow Transplant. 2003 Jun;31(11):1009-13
references: 12774052
references: Blood. 2001 Aug 1;98(3):579-85
references: 11468153
references: Bone Marrow Transplant. 2009 Nov;44(9):559-69
references: 19701250
references: J Clin Oncol. 2001 Sep 1;19(17):3771-9
references: 11533101
references: Bone Marrow Transplant. 2006 May;37(9):811-7
references: 16532018
references: Clin Exp Med. 2004 Oct;4(2):78-85
references: 15672944
references: Clin Lymphoma Myeloma. 2007 Jan;7(4):315-8
references: 17324341
references: Leuk Lymphoma. 2005 Sep;46(9):1287-94
references: 16109605
references: Immunol Res. 2003;28(1):1-11
references: 12947220
references: J Hematother Stem Cell Res. 2001 Aug;10(4):465-80
references: 11522230
references: Am J Hematol. 2009 Jan;84(1):21-8
references: 19006229
references: Bone Marrow Transplant. 2005 Dec;36(12):1049-52
references: 16247431
references: Blood. 2001 Jan 1;97(1):14-32
references: 11133738
references: Biol Blood Marrow Transplant. 2008 Jul;14(7):807-16
references: 18541201
references: Bone Marrow Transplant. 2004 Feb;33(3):291-8
references: 14676784
references: Clin Cancer Res. 2005 Feb 1;11(3):1210-8
references: 15709191
references: Nature. 2000 Nov 2;408(6808):57-63
references: 11081504
references: Cytotherapy. 2008;10(5):507-17
references: 18608354
references: Bone Marrow Transplant. 2006 Jun;37(11):1037-42
references: 16708062
references: J Clin Oncol. 2001 Feb 1;19(3):634-44
references: 11157013
references: Leuk Lymphoma. 2003 Jun;44(6):997-1000
references: 12854901
references: Leukemia. 2004 Jun;18(6):1156-8
references: 15042107
references: Br J Haematol. 2002 Jun;117(3):629-33
references: 12028034
references: Bone Marrow Transplant. 2004 Jul;34(1):43-9
references: 15107814
references: Bone Marrow Transplant. 2006 May;37(9):865-71
references: 16532015
references: Bone Marrow Transplant. 2001 Nov;28(9):865-71
references: 11781647
references: Hematology. 2006 Jun;11(3):165-70
references: 17325956